Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...
Libevitug works by blocking hepatitis B and D viruses from entering liver cells, targeting the PreS1 domain of the viral ...
Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...
Chinese biotech Huahui Health has won conditional approval for Libevitug (libevitug) to treat adults with chronic hepatitis D ...
Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...
China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the ...
The Hepatitis B Co-care Scheme, allowing eligible individuals to receive a hepatitis B risk assessment, screening and ...
The CHB therapeutics market offers growth opportunities via emerging functional cures like bepirovirsen and selgantolimod, amidst challenges from patent expiries and generic erosion. Strategic R&D, ...
(Yicai) Jan. 21 -- Chinese innovative pharmaceutical company Kawin Technology plummeted today after withdrawing its ...
Authorities say screening will cover people born in Hong Kong in or before 1988 with family members or sexual partners who ...
LONDON, Jan 7 (Reuters) - GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results